Home/Protocols/ARA-290
Protocol Reference
Human trial data

ARA-290 protocol

ARA-290 (cibinetide, erythropoietin-derived peptide). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
Healing & Repair
Common vials
Not stocked by our featured supplier
Half-life
Very short — minutes
Route in the literature
Subcutaneous
Evidence level
Human trial data

How ARA-290 works

An 11-amino-acid peptide derived from the helix-B domain of erythropoietin. It engages the innate repair receptor without the erythropoietic activity of EPO, so it does not raise haematocrit.

ARA-290 dosing schedule

From the phase 2 trial in sarcoidosis-associated small-fibre neuropathy, one of the few compounds in this category with genuine human trial dosing.

PhaseAmountFrequencyNotes
Trial arm4 mgDaily, subcutaneousThe amount used in the sarcoidosis small-fibre neuropathy trial.

Study length: 28 days in the phase 2 trial.

Source for this schedule: Dahan A et al., ARA-290 in sarcoidosis patients with symptoms of small fibre neuropathy, phase 2. This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for ARA-290: Not stocked by our featured supplier.

  1. Wipe the stoppers of both vials with an alcohol swab and let them dry.
  2. Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
  3. Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
  4. Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.

Open the ARA-290 calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Supplies math

Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.

Vials
Doses per vial = vial size in mg divided by your per-dose amount in mg. A Not stocked by our featured supplier vial at 500 mcg per dose is 20 doses; scale for your own numbers.
Syringes
One sterile U-100 insulin syringe per injection, plus roughly 10% spares for bent tips and mis-draws. Daily protocols run 30 or 31 per month.
Bacteriostatic water
1 to 3 mL per vial reconstituted. A single 10 mL bottle covers 3 to 10 vials, so one bottle usually outlasts several vials.
Alcohol swabs
Two per injection: one for the vial stopper, one for the site. A 100-count box covers about 7 weeks of daily work.

Subcutaneous technique and practical notes

General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.

Fresh sterile syringe, every time
Reusing needles dulls the tip, hurts more, and is the easiest contamination route. Dispose of used syringes in a sharps container, not the bin.
Rotate sites
Abdomen (5 cm clear of the navel), thighs, upper arms. Rotating systematically prevents localised irritation and lipohypertrophy.
Slow and steady
Pinch a skinfold, insert at 45–90°, inject slowly, and wait a few seconds before withdrawing. Subcutaneous injections are not aspirated.
Write it down
Log the date, amount and site. A record is the only way to keep any research protocol consistent — and the first thing to review if anything looks off.

Reported effects

  • Reported as well tolerated in the phase 2 work, with no increase in haematocrit — the specific advantage over EPO itself.
  • Evidence base is small and indication-specific.

Sourcing ARA-290

Our featured supplier does not stock this compound, and we are not going to point you at a vendor we have not looked at. Use the COA checklist on whoever you do buy from, and check the batch number on the certificate against the vial you receive.

COA checklist → How we vet suppliers

Sources and further reading

For laboratory research use only. This page documents what the published literature reports about ARA-290. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →